Investigation of the Effect of Doxycycline in the Treatment of Keratoconus

Investigation of the Effect of Oral Doxycycline Consumption Following Corneal Cross-linking (CCL) on Corneal Biomechanics Improvement in Patients with Keratoconus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20110811007297N10

Enrollment

Registered

2025-02-09

Start date

2025-02-03

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Keratoconus. Keratoconus

Interventions

Intervention 1: Intervention group:Patients will receive doxycycline tablets orally at a dosage of 100 mg every 12 hours for a duration of 30 days, along with routine eye drops. Intervention 2: Contro

Eligibility

Sex/Gender

All

Age

12 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients with keratoconus who are candidates for corneal cross-linking surgery

Exclusion criteria

Exclusion criteria: Patients with diagnoses other than keratoconus History of previous treatments for keratoconus History of allergy to doxycycline Inability to access the patient for follow-up after surgery Presence of concomitant ocular or systemic diseases

Design outcomes

Primary

Measure	Time frame
Corneal biomechanics after Tab doxycycline administration following keratoconus surgery. Timepoint: Before the procedure and 6 months after the surgery. Method of measurement: Pentacam and Corvis.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmir Khosravi

Shiraz University of Medical Sciences

amir11khosravi@gmail.com+98 71 3629 1779

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026